top of page

Project Code

Target

Indicant

MOA & Molecule Type

Phase 3

Phase 2

Phase 1

Preclinical

Peptide Receptor Radionuclide Therapy

Renal cancer

CAIX

Late

Discovery

  Peptide Receptor Radionuclide Therapy

(Pro-Drug)

Neuroendocrine tumor

SSTR2

 PRRT, PDC, Pro-drug

solid cancer

FAP

CNP

Achondrogenesis

NPR-B

​Pipeline

CBT-005

Early

Discovery

Kidney Cancer

Neuroendocrine Tumor

Solid Cancer

Achondroplasia

Project Code

Target

Indicant

MOA & Molecule Type

Phase 3

Phase 2

Phase 1

Preclinical

Peptide Receptor

Radionuclide Therapy

CAIX

CBT-001

Late

Discovery

  Peptide Receptor

Radionuclide

Therapy(Pro-Drug)

SSTR2

 PRRT, PDC, Pro-drug

FAP-α

CBT-004

CNP

NPR-B

CBT-005

​Pipeline

Early

Discovery

Target: NPR-B

Indicant: Achondrogenesis

MOA & Molecule Type: Peptide CNP

Development stage: R&D

Summary: Achondrogenesis is a disease that causes problems in bone growth of cartilage and is caused by mutations in the FGFR3 gene and failure to produce proper bones.
In order to prevent the proliferation and differentiation of cartilage cells from being inhibited, CNP (C-type natural peptide) must activate NPR-B in cartilage to suppress the activity of RFP, an intermediate product in the FGFR3 signaling process.
Currently, the product approved as a treatment is Voxzogo one substance and has been approved as a "rare drug." Our company compared to existing treatments, the company has increased stability in the body by using D-amino acid and is developing treatments that are cartilage-specific and strong binding to NPR-B through material advancement.

CBT-005

bottom of page